Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 3/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4532055 | 0.87 | NPC1 (0.43) | NPC1RAB9ASLC6A5CTSLCTSB | |
| SCHEMBL4866845 | 0.87 | NPC1 (0.43) | NPC1RAB9ASLC6A5CTSLCTSB | |
| SCHEMBL4866936 | 0.86 | NPC1 (0.44) | NPC1RAB9ASLC6A5CTSLCTSB | |
| SCHEMBL18063149 | 0.81 | TACR1 (0.43) | SLC6A5CTSLCTSBCTSSMMP1 | |
| SCHEMBL4907162 | 0.80 | TACR1 (0.47) | NPC1RAB9AMAPTMMP1CYP4F2 | |
| SCHEMBL14881069 | 0.79 | TACR1 (0.44) | SLC6A5CTSLCTSBCTSSMAPT | |
| SCHEMBL13904681 | 0.78 | ALDH1A1 (0.46) | CTSLCTSBCTSS | |
| SCHEMBL30683842 | 0.78 | TACR1 (0.48) | NPC1RAB9AMAPTCYP4F2CYP4A11 | |
| SCHEMBL27994909 | 0.77 | MEN1 (0.49) | NPC1RAB9AMAPTCYP4F2CYP4A11 | |
| SCHEMBL4870545 | 0.77 | NPC1 (0.41) | NPC1RAB9AEPHX2FKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318445-A1 | PDF INHIBITORS | NORVARTIS AG (CH) | 2009-12-24 | — | — | US | disclosed |
| US-20090318445-A1 | PDF INHIBITORS | NORVARTIS AG (CH) | 2009-12-24 | — | — | US | disclosed |
| EP-1973898-A1 | PDF INHIBITORS | Novartis AG (CH) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007077186-A1 | PDF INHIBITORS | NOVARTIS AG (CH) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318445-A1 | PDF INHIBITORS | PDF, TIMP3, MMP2 | NPC1 1906/4885RAB9A 1316/4885SLC6A5 3289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.